| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement
Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of 2026
Tech transfer underway with validation batch manufacturing expected to begin in 2026
Evofem and Windtree exploring other partnerships
WARRINGTON, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NASDAQ:WINT) today announced that it has contracted with a pharmaceutical manufacturer in China to produce Evofem's hormone-free contraceptive product, PHEXXI® (lactic acid, citric acid and potassium bitartrate), at a cost that is significantly below current levels.
With the tech transfer process now underway, and early-stage manufacturing expected to begin later this year, Windtree anticipates the arrangement will generate revenue for Windtree, while reducing Evofem's cost to manufacture the PHEXXI by more than 50% by year end 2026.
